Dana-Farber/Boston Children's Cancer and Blood Disorders Center recognized for exceptional outcomes in pediatric stem cell ...

Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, ...

Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...

Mesenchymal stem cells are adult stem cells found in several places ... improvement in safety of aHSCT over the years. The rate of transplant-related mortality was 7.3% between 1995 and 2000.

or preparing to have your own stem cells collected for use in your transplant later. We will guide you, step by step, as you get ready. When you arrive at Fred Hutch for your transplant, your ...

(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...

Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

Omeros (OMER) announced statistical sensitivity analysis results related to the primary endpoint analysis for narsoplimab, Omeros’ monoclonal ...